Login to Your Account

Would shingle: FDA panel says yes to GSK's vaccine

By Randy Osborne
Staff Writer

Wednesday, September 13, 2017

Shingrix (varicella zoster vaccine [recombinant], adjuvanted) from Glaxosmithkline plc sailed through a hearing by the FDA's Vaccines and Related Biological Products Committee, with panelists voting 11-0 in favor of the product's efficacy and safety in people 50 years of age and beyond.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription